医学と薬学　77/6　2020年6月号

出版社： 自然科学社
発行日： 2020-05-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： パーキンソン病診療ガイドライン2018以降の新しい展開
電子書籍版： 2020-05-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　パーキンソン病診療ガイドライン2018以降の新しい展開

    序文
    パーキンソン病の診断基準，MDS-UPDRSその後の評価
    L-ドパ：今後の治療における位置付けと最新情報
    アポモルフィンを含むドパミンアゴニスト最新のコンセプト
    MAO-B，ゾニサミドの最新のコンセプト
    A2A阻害剤，COMT阻害剤の最新情報
    リハビリテーション療法および深部脳刺激，MRガイド下集束超音波治療の最先端

    臨床試験
    　ガランタミンOD錠8mg「日医工」の健康成人における生物学的同等性試験
    　メマンチン塩酸塩OD錠20mg「日医工」の健康成人における生物学的同等性試験

    薬理・薬剤
    　メマンチン塩酸塩OD錠の製造およびその品質評価 全星薬品工業株式会社

    Diagnosis
    　イムノクロマト法を用いた新型コロナウイルスSARS-CoV-2抗原検出試薬の開発
    　CA19-9の機種間による測定値差の検討と考察

    Cosmetic
    　プラセンタエキス配合頬専用ピーリングジェルのシミ改善効果　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 パーキンソン病診療ガイドライン 2018以降の新しい展開】

P.866 掲載の参考文献
1) Rizzo G, Copetti M, Arcuti S, et al : Accuracy of clinical diagnosis of Parkinson disease : A systematic review and meta-analysis. Neurology 86 (6) : 566-576. 2016.
PubMed
2) Gibb WR, Lees AJ : The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (6) : 745-752, 1988.
 
3) Hughes AJ, Daniel SE, Kilford L, et al : Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (3) : 181-184, 1992.
 
4) Postuma RB, Berg D, Stern M, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 (12) : 1591-1601, 2015.
PubMed
5) Berg D, Adler CH, Bloem BR, et al : Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord 33 (10) : 1643-1646, 2018.
PubMed
6) Goetz CG, Tilley BC, Shaftman SR, et al : Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) : scale presentation and clinimetric testing results. Mov Disord 23 (15) : 2129-2170, 2008.
PubMed
7) Hughes AJ, Daniel SE, Lees AJ : Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (8) : 1497-1499, 2001.
PubMed
8) 厚生労働省 : 指定難病制度に於ける各疾患診断. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000062437.html (2020年2月15日アクセス)
 
9) Berg D, Postuma RB, Adler CH, et al : MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 (12) : 1600-1611, 2015.
PubMed
10) Malek N, Lawton MA, Grosset KA, et al : Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism Relat Disord 40 : 40-46, 2017.
 
11) Postuma RB, Poewe W, Litvan I, et al : Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 33 (10) : 1601-1608, 2018.
PubMed
12) Fahn S , Elton RL : Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, vol 2. (ed. by Fahn S, Marsden CD, Calne DB, et al), pp.153-163, Macmillan Health Care Information, NJ, 1987.
 
13) International Parkinson and Movement Disorder Society. https://www.movementdisorders.org (2020年2月15日アクセス)
 
14) Goetz CG, Stebbins GT, Chmura TA, et al : Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale : (MDS-UPDRS). Mov Disord 25 (9) : 1190-1194, 2010.
PubMed
15) Peto V, Jenkinson C, Fitzpatrick R : PDQ-39 : a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 245 (Suppl 1) : S10-14, 1998.
 
16) Skorvanek M, Martinez-Martin P, Kovacs N, et al : Relationship between the MDS-UPDRS and Quality of Life : A large multicenter study of 3206 patients. Parkinsonism Relat Disord 52 : 83-89, 2018.
PubMed
17) Thorp JE, Adamczyk PG, Ploeg HL, et al : Monitoring Motor Symptoms During Activities of Daily Living in Individuals With Parkinson's Disease. Front Neurol 9 : 1036, 2018.
PubMed
P.872 掲載の参考文献
1) Freitas ME, Ruiz-Lopez M, Fox SH : Novel Levodopa Formulations for Parkinson's Disease. CNS Drugs 30 (11) : 1079-1095, 2016.
PubMed
2) Hauser RA, Ellenbogen AL, Metman LV, et al : Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 26 (12) : 2246-2252, 2011.
 
3) Hauser RA, Hsu A, Kell S, et al : Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations : a phase 3 randomised, double-blind trial. Lancet Neurol 12 (4) : 346-356, 2013.
PubMed
4) Stocchi F, Hsu A, Khanna S, et al : Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 20 (12) : 1335-1340, 2014.
PubMed
5) Verhagen Metman L, Stover N, Chen C, et al : Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Mov Disord 30 (9) : 1222-1228, 2015.
PubMed
6) Trenkwalder C, Kuoppamaki M, Vahteristo M, et al : Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. Neurology 92 (13) : e1487-e1496, 2019.
 
7) Olanow CW, Kieburtz K, Odin P, et al : Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease : a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13 (2) : 141-149, 2014.
PubMed
8) Ishibashi Y, Shimo Y, Yube Y, et al : Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson's disease. Scand J Gastroenterol 54 (6) : 787-792, 2019.
PubMed
9) Muller T, van Laar T, Cornblath DR, et al : Peripheral neuropathy in Parkinson's disease : levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19 (5) : 501-507, 2013
 
10) Navon N : The Accordion Pill(R) : unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs. Ther Deliv 10 (7) : 433-442, 2019.
 
11) LeWitt PA, Giladi N, Navon N : Pharmacokinetics and efficacy of a novel formulation of carbidopa- levodopa (Accordion Pill(R)) in Parkinson's disease. Parkinsonism Relat Disord 65 : 131-138, 2019.
 
12) LeWitt PA, Huff FJ, Hauser RA, et al : Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 29 (1) : 75-82, 2014.
PubMed
13) LeWitt PA, Hauser RA, Pahwa R, et al : Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18 (2) : 145-154, 2019.
PubMed
14) Kianirad Y, Simuni T : Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. Curr Neurol Neurosci Rep 16 (4) : 34, 2016
PubMed
15) Nyholm D, Ehrnebo M, Lewander T, et al : Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand 127 (2) : 124-132, 2013.
PubMed
16) Senek M, Aquilonius SM, Askmark H, et al : Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. Eur J Clin Pharmacol 73 (5) : 563-571, 2017.
PubMed
17) Mor DE, Daniels MJ, Ischiropoulos H : The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration. Mov Disord 34 (2) : 167-179, 2019.
PubMed
18) Titova N, Levin O, Katunina E, et al : 'Levodopa Phobia' : a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis 4 : 31, 2018.
 
P.878 掲載の参考文献
1) Gupta HV, Lyons KE, Pahwa R : Old Drugs, New Delivery Systems in Parkinson's Disease. Drugs Aging 36 (9) : 807-821, 2019.
PubMed
2) Stocchi F, Ruggieri S, Brughitta G, et al : Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. J Neural Transm Suppl 22 : 209-218, 1986.
PubMed
3) Antonini A, Tolosa E, Mizuno Y, et al : A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 8 (10) : 929-937, 2009.
PubMed
4) 日本神経学会監, パーキンソン病診療ガイドライン作成委員会編 : パーキンソン病診療ガイドライン 2018, 医学書院, 東京, 2018.
 
5) Group PDMC, Gray R, Ives N, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet 384 (9949) : 1196-1205, 2014.
 
6) Katzenschlager R, Head J, Schrag A, et al : Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71 (7) : 474-480, 2008.
PubMed
7) Fox SH, Katzenschlager R, Lim SY, et al : The Movement Disorder Society Evidence-Based Medicine Review Update : Treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 (Suppl 3) : S2-41, 2011.
 
8) Fox SH, Katzenschlager R, Lim SY, et al : International Parkinson and movement disorder society evidence-based medicine review : Update on treatments for the motor symptoms of Parkinson' s disease. Mov Disord 33 (8) : 1248-1266, 2018.
PubMed
9) Barone P, Poewe W, Albrecht S, et al : Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 (6) : 573-580, 2010.
PubMed
10) Rektorova I, Rektor I, Bares M, et al : Pramipexole and pergolide in the treatment of depression in Parkinson's disease : a national multicentre prospective randomized study. Eur J Neurol 10 (4) : 399-406, 2003.
PubMed
11) Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al : Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 19 (7) : 660-665, 2013.
 
12) Antonini A, Bauer L, Dohin E, et al : Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms-results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol 22 (10) : 1400-1407, 2015.
PubMed
13) Wood M, Dubois V, Scheller D, et al : Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol 172 (4) : 1124-1135, 2015.
PubMed
14) Ikeda K, Hirayama T, Takazawa T, et al : Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease : An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists. Intern Med 55 (19) : 2765-2769, 2016.
 
15) Hirano M, Isono C, Sakamoto H, et al : Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease. Dysphagia 30 (4) : 452-456, 2015.
PubMed
16) Hirano M, Isono C, Fukuda K, et al : Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease. J Neurol Sci 404 : 5-10, 2019.
PubMed
17) Schirinzi T, Imbriani P, D'Elia A, et al : Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings. Clin Neurol Neurosurg 156 : 63-65, 2017.
PubMed
18) Brusa L, Petta F, Farullo G, et al : Rotigotine Effects on Bladder Function in Patients with Parkinson's Disease. Mov Disord Clin Pract 4 (4) : 586-589, 2017.
PubMed
19) Olanow CW, Factor SA, Espay AJ, et al : A pomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19 (2) : 135-144, 2020.
 
20) Grosset KA, Malek N, Morgan F, et al : Inhaled dry powder a pomorphine (VR040) for 'off' periods in Parkinson's disease : an in-clinic double-blind dose ranging study. Acta Neurol Scand 128 (3) : 166-171, 2013.
 
21) Gurrell R, Duvvuri S, Sun P, et al : A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. Clin Drug Investig 38 (6) : 509-517, 2018.
 
22) Papapetropoulos S, Liu W, Duvvuri S, et al : Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration. Neurodegener Dis 18 (5-6) : 262-269, 2018.
 
P.885 掲載の参考文献
1) PD Med Collaborative Group, Gray R, Ives N, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet 384 : 1196-1205, 2014.
 
2) Hauser RA, Li R, Perez A, et al : Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease : An Analysis of NET-PD LS1. J Parkinsons Dis 7 : 117-127, 2017.
PubMed
3) Kitaichi Y, Inoue T, Mitsui N, et al : Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder : a case report. Neuropsychiatr Dis Treat 9 : 1591-1594, 2013.
PubMed
4) Miklya I : The significance of selegiline/ (-) -deprenyl after 50 years in research and therapy (1965-2015). Mol Psychiatry 21 : 1499-1503, 2016.
PubMed
5) Harsing LG Jr, Magyar K, Tekes K, et al : Inhibition by deprenyl of dopamine uptake in rat striatum : a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 31 : 297-307, 1979.
PubMed
6) Wu Y, Kazumura K, Maruyama W, et al : Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore : a novel anti-apoptotic function for neuroprotection. J Neural Transm (Vienna) 122 : 1399-1407, 2015.
PubMed
7) Teo KC, Ho SL : Monoamine oxidase-B (MAO-B) inhibitors : implications for disease-modification in Parkinson's disease. Transl Neurodegener 2 : 19, 2013.
 
8) Hattori N, Takeda A, Takeda S, et al : Rasagiline monotherapy in early Parkinson's disease : A phase 3, randomized study in Japan. Parkinsonism Relat Disord 60, 146-152, 2019.
PubMed
9) Lew MF : Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci 123 : 859-865, 2013.
PubMed
10) Jankovic J, Berkovich E, Eyal E, et al : Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease : post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 20 : 640-643, 2014.
PubMed
11) Morari M, Brugnoli A, Pisano CA, et al : Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. J Pharmacol Exp Ther 364 : 198-206, 2018.
PubMed
12) Gardoni F, Morari M, Kulisevsky J, et al : Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J Pharmacol Exp Ther 367, 442-451, 2018.
 
13) Miwa H, Hama K, Kajimoto Y, et al : Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord 14 : 33-36, 2008.
PubMed
14) Yamamura S, Ohoyama K, Nagase H, et al : Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 57 : 322-331, 2009.
PubMed
15) Fukuyama K, Tanahashi S, Hoshikawa, et al : Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology 76 Pt A : 137-145, 2014.
 
16) Miwa H, Kondo T : T-type calcium channel as a new therapeutic target for tremor. Cerebellum 10 : 563-569, 2011.
PubMed
P.892 掲載の参考文献
1) Vorovenci, R J, Antonini A : The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Rev Neurother 15 : 1383-1390, 2015.
PubMed
2) ノウリアスト錠 20mg に関する資料, 協和発酵キリン株式会社, https://www.pmda.go.jp/drugs/2013/P201300035/index.html
 
3) Ishibashi K, Miura Y, Wagatsuma K, et al : Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET. Neuropharmacology 143 : 106-112, 2018.
 
4) Sako, W, Murakami, N, Motohama, K, et al : The effect of istradefylline for Parkinson's disease : A meta-analysis. Sci Rep-uk 7, 18018, 2017.
PubMed
5) FDA NEWS RELEASE : FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease, https://www.fda.gov/newsevents/press-announcements/fda-approvesnew-add-drug-treat-episodes-adults-parkinsonsdisease
 
6) Takahashi, M, Fujita, M, Asai, N, et al : Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmaco 19, 1-8, 2018.
 
7) Iijima M, Orimo S, Terashi H, et al : Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study. Expert Opin Pharmaco 20, 1405-1411, 2019.
 
8) Matsuura K, Kajikawa H, Tabei KI, et al : The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson's disease. Neurosci Lett 662 : 158-161, 2018.
PubMed
9) Suzuki, K, Miyamoto, T, Miyamoto, M, et al : Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease? J Neurol Sci 385 : 131-133, 2018.
PubMed
10) Fujioka S, Yoshida R, Nose K, et al : A new therapeutic strategy with istradefylline for postural deformities in Parkinson's disease. Neurol Neurochir Pol 53 : 291-295, 2018.
 
11) Yasuda Y : Reversible istradefylline-induced pleurothotonus in a patient with Parkinson's disease : A case report and literature review. Eneurologicalsci 13, 5-7, 2018.
 
12) Suzuki K, Miyamoto M, Miyamoto T, et al : Istradefylline improves daytime sleepiness in patients with Parkinson's disease : An open-label, 3-month study. J Neurol Sci 380 : 230-233, 2017.
PubMed
13) Reyes, AJ, Ramcharan K, Giddings SL, et al : Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease. Tremor Other Hyperkinetic Movements 8 : 521, 2011.
 
14) Quiroz C, Gulyani S, Ruiqian W, et al : Adenosine receptors as markers of brain iron deficiency : Implications for Restless Legs Syndrome. Neuropharmacology 111 : 160-168, 2016.
PubMed
15) Nagayama H, Kano O, Murakami H, et al : Effect of istradefylline on mood disorders in Parkinson's disease. J Neurol Sci 396 : 78-83, 2018.
PubMed
16) Kon T, Ueno T, Haga R, et al : The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. Brain Behav 8 : e01036 2018.
PubMed
17) Marin-Lahoz J, Sampedro F, Martinez-Horta S, et al : Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. Ann Neurol 86 : 762-769, 2019.
PubMed
18) Kitta T, Yabe I, Kanno Y, et al : Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients. Clin Neuropharmacol 41 : 98-102, 2018.
PubMed
19) Trenkwalder C, Kuoppamaki M, Vahteristo M, et al : Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. Neurology 92 : 10.1212/WNL.0000000000007173, 2019.
 
20) Ferreira JJ, Lees A, Rocha JF, et al : Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Lancet Neurology 15 : 154-165, 2016.
PubMed
21) Lees AJ, Ferreira J, Rascol O, et al : Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations : A Randomized Clinical Trial. JAMA Neurol 74 (2) : 197-206, 2017.
PubMed
22) Salamon A, Zadori D, Szpisjak L, et al : Opicapone for the treatment of Parkinson's disease : an update. Expert Opin Pharmaco 20 : 1-7, 2019.
 
23) Fabbri M, Ferreira JJ, Lees A, et al : Opicapone for the treatment of Parkinson's disease : A review of a new licensed medicine. Movement Disord 33 : 1528-1539, 2018.
PubMed
24) Aho VTE, Pereira PAB, Voutilainen S et al : Gut microbiota in Parkinson's disease : Temporal stability and relations to disease progression. Ebiomedicine 44 : 691-707, 2019.
PubMed
25) Grun D, Zimmer VC, Kauffmann J et al : Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease. Parkinsonism Relat D 70 : 20-22, 2019.
PubMed
26) Weis S, Schwiertz, A, Unger MM, et al : Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota. Npj Park Dis 5 : 28, 2019.
 
P.898 掲載の参考文献
1) 日本神経学会監, パーキンソン病診療ガイドライン作成委員会編 : パーキンソン病診療ガイドライン 2018, 医学書院, 東京, 2018.
 
2) Fox SH, Katzenschlager R, Lim SY, et al : International Parkinson and movement disorder society evidence-based medicine review : Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 33 (8) : 1248-1266, 2018.
PubMed
3) Clarke CE, Patel S, Ives N, et al : Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease : A Randomized Clinical Trial. JAMA Neurol 73 (3) : 291-299, 2016.
PubMed
4) Mak MK, Wong-Yu IS, Shen X, et al : Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol 13 (11) : 689-703, 2017.
PubMed
5) da Silva FC, Iop RDR, de Oliveira LC, et al : Effects of physical exercise programs on cognitive function in Parkinson's disease patients : A systematic review of randomized controlled trials of the last 10 years. PLoS One 13 (2) : e0193113, 2018.
PubMed
6) Ni M, Hazzard JB, Signorile JF, et al : Exercise Guidelines for Gait Function in Parkinson's Disease : A Systematic Review and Meta-analysis. Neurorehabil Neural Repair 32 (10) : 872-886, 2018.
PubMed
7) Cosentino C, Baccini M, Putzolu M, et al : Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease : A Systematic Review and Meta-Analyses. Mov Disord 35 (4) : 523-536, 2020.
PubMed
8) Carroll LM, Volpe D, Morris ME, et al : Aquatic Exercise Therapy for People With Parkinson Disease : A Randomized Controlled Trial. Arch Phys Med Rehabil 98 (4) : 631-638, 2017.
PubMed
9) Clerici I, Maestri R, Bonetti F, et al : Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease : A Randomized Controlled Trial. Phys Ther 99 (5) : 591-600, 2019.
PubMed
10) Terrens AF, Soh SE, Morgan PE : The efficacy and feasibility of aquatic physiotherapy for people with Parkinson's disease : a systematic review. Disabil Rehabil 40 (24) : 2847-2856, 2018.
PubMed
11) Carroll LM, Morris ME, O'Connor WT, et al : Is Aquatic Therapy Optimally Prescribed for Parkinson's Disease? A Systematic Review and Meta-Analysis. J Parkinsons Dis 10 (1) : 59-76, 2020.
PubMed
12) van der Kolk NM, de Vries NM, Kessels RPC, et al : Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease : a double-blind, randomised controlled trial. Lancet Neurol 18 (11) : 998-1008, 2019.
PubMed
13) Amara AW, Wood KH, Joop A, et al : Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease. Mov Disord, 2020. doi : 10.1002/mds.28009. [Epub ahead of print]
 
14) Mirelman A, Rochester L, Maidan I, et al : Addition of a non-immersive virtual reality component to treadmill training to reduce fall risk in older adults (V-TIME) : a randomised controlled trial. Lancet 388 (10050) : 1170-1182 2016.
 
15) Triegaardt J, Han TS, Sada C, et al : The role of virtual reality on outcomes in rehabilitation of Parkinson's disease: meta-analysis and systematic review in 1031 participants. Neurol Sci 41 (3) : 529-536, 2020.
PubMed
16) Dockx K, Bekkers EM, Van den Bergh V, et al : Virtual reality for rehabilitation in Parkinson's disease. Cochrane Database Syst Rev 12 : CD010760, 2016.
PubMed
17) Lei C, Sunzi K, Dai F, et al : Effects of virtual reality rehabilitation training on gait and balance in patients with Parkinson's disease : A systematic review. PLoS One 14 (11) : e0224819, 2019.
PubMed
18) Chen Y, Gao Q, He CQ, et al : Effect of Virtual Reality on Balance in Individuals With Parkinson Disease : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Phys Ther, 2020. doi : 10.1093/ptj/pzaa042. [Epub ahead of print]
 
19) Carpinella I, Cattaneo D, Bonora G, et al : Wearable Sensor-Based Biofeedback Training for Balance and Gait in Parkinson Disease : A Pilot Randomized Controlled Trial. Arch Phys Med Rehabil 98 (4) : 622-630, 2017.
PubMed
20) Ginis P, Nieuwboer A, Dorfman M, et al : Feasibility and effects of home-based smartphone-delivered automated feedback training for gait in people with Parkinson's disease : A pilot randomized controlled trial. Parkinsonism Relat Disord 22 : 28-34, 2016.
PubMed
21) Nousia A, Martzoukou M, Tsouris Z, et al : The Beneficial Effects of Computer-Based Cognitive Training in Parkinson's Disease : A Systematic Review. Arch Clin Neuropsychol, 2020. doi : 10.1093/arclin/acz080. [Epub ahead of print]
 
22) Odekerken VJ, Boel JA, Schmand BA, et al : GPi vs STN deep brain stimulation for Parkinson disease : Three-year follow-up. Neurology 86 (8) : 755-761, 2016.
PubMed
23) Schuepbach WM, Rau J, Knudsen K, et al : Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 368 (7) : 610-622, 2013.
PubMed
24) Lhommee E, Wojtecki L, Czernecki V, et al : Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial) : secondary analysis of an open-label randomised trial. Lancet Neurol 17 (3) : 223-231, 2018.
PubMed
25) Schuepbach WMM, Tonder L, Schnitzler A, et al : Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology 92 (10) : e1109-e1120, 2019.
PubMed
26) Barbe MT, Tonder L, Krack P, et al : Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications. Mov Disord 35 (1) : 82-90, 2020.
PubMed
27) Hacker ML, DeLong MR, Turchan M, et al : Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology 91 (5) : e463-e471, 2018.
PubMed
28) Dembek TA, Reker P, Visser-Vandewalle V, et al : Directional DBS increases side-effect thresholds-A prospective, double-blind trial. Mov Disord 32 (10) : 1380-1388, 2017.
PubMed
29) Liu XD, Bao Y, Liu GJ : Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol 10 : 934, 2019.
PubMed
30) van Poppelen D, Sisodia V, de Haan RJ, et al : Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease-the INfusion VErsus STimulation (NVEST) study. BMC Neurol 20 (1) : 40, 2020.
 
31) Blomstedt P, Stenmark Persson R, Hariz GM, et al : Deep brain stimulation in the caudal zona incerta versus best medical treatment in patients with Parkinson's disease : a randomised blinded evaluation. J Neurol Neurosurg Psychiatry 89 (7) : 710-716, 2018.
PubMed
32) Gratwicke J, Zrinzo L, Kahan J, et al : Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia : A Randomized Clinical Trial. JAMA Neurol 75 (2) : 169-178, 2018.
PubMed
33) Bond AE, Shah BB, Huss DS, et al : Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease : A Randomized Clinical Trial. JAMA Neurol 74 (12) : 1412-1418, 2017.
PubMed
34) Sperling SA, Shah BB, Barrett MJ, et al : Focused ultrasound thalamotomy in Parkinson disease : Nonmotor outcomes and quality of life. Neurology 91 (14) : e1275-e1284, 2018.
PubMed
35) Xu Y, He Q, Wang M, et al : Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson's disease : a systematic review. Neurosurg Rev, 2019. doi : 10.1007/s10143-019-01216-y. [Epub ahead of print]
 
36) Gallay MN, Moser D, Rossi F, et al : MRg-FUS Pallidothalamic Tractotomy for Chronic Therapy-Resistant Parkinson's Disease in 51 Consecutive Patients : Single Center Experience. Front Surg 6 : 76, 2020.
 

【臨床試験】

P.911 掲載の参考文献
1) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (薬食審査発0229第10号 平成24年2月29日)
 
2) 医薬品の製造 (輸入) 承認申請に際して添付すべき安定性試験成績の取り扱いについて (薬審第43号 平成3年2月15日)
 
P.923 掲載の参考文献
1) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (薬食審査発0229第10号 平成24年2月29日)
 
2) 医薬品の製造 (輸入) 承認申請に際して添付すべき安定性試験成績の取り扱いについて (薬審第43号 平成3年2月15日)
 

【薬理・薬剤】

P.936 掲載の参考文献
1) 医薬品インタビューフォーム メマリー(R) OD錠 5mg, メマリー(R) OD錠 10mg, メマリー(R) OD錠 20mg. 2017年4月改定 (第12版)
 
2) 増田義典 : 口腔内崩壊錠の進化・深化を支える添加物. PHARM TECH JAPAN 31 (4) : 710-715, 2015.
 
3) 山崎淳治, 飛松佳江, 中野善夫, 他 : アンブロキソール塩酸塩徐放 OD 45mg「ZE」の製剤特性. 医学と薬学 71 (6) : 1029-1036, 2014.
Medical*Online
4) 清水寿弘 : 患者ベネフィットを考えた製剤の知識を服薬支援に活かす口腔内速崩壊錠の優れた製剤技術に学ぶ-タケプロンOD錠を中心に-. PHARM TECH JAPAN 28 (2) : 275-279, 2012.
 
5) 内田享弘 : 味覚センサーを用いた医薬品の服用性の総合評価. YAKUGAKU ZASSHI 134 (3) : 317-323, 2014.
 
6) 安定性試験実施方法のガイドライン (平成3年2月15日 薬審第43号)
 
7) 後発医薬品の生物学的同等性試験ガイドライン (平成9年12月22日付け医薬審第487号一部改正平成24年2月29日薬食審査発第0229第10号)
 
8) 含量が異なる経口固形製剤の生物学的同等性試験ガイドライン (平成12年2月14日 医薬審第64号医薬安全局審査管理課長通知 一部改正平成24年2月29日薬食審査発第0229第10号)
 

【Diagnosis】

P.944 掲載の参考文献
1) Wu Z, McGoogan, J : Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA 323 (13) : 1239-1242, 2020.
PubMed
2) 新型コロナウイルス感染症 (COVID-19) 診療の手引き・第1版
 
3) WHO Director-General's opening remarks at the media briefing on COVID19-11-March 2020.
 
4) Gorbalenya A, Baker S, Baric R, et al : The species Severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5 : 536-544, 2020.
PubMed
5) Kogaki H, Uchida Y, Fujii N, et al : Novel rapid immunochromatographic test based on an enzyme immunoassay for detecting nucleocapsid antigen in SARS-associated coronavirus. J Clin Lab Anal 19 (4) : 150-159, 2005.
 
6) Ohnishi K, Sakaguchi M, Kaji T, et al : Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn J Infect Dis 58 (2) : 88-94, 2005.
PubMed
7) Shirato K, Kawase M, Matsuyama S : Wildtype human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 517 : 9-15, 2017.
PubMed
8) 新型コロナウイルス SARS-CoV-2のゲノム分子疫学調査 https://www.niid.go.jp/niid/ja/basic-science/467-genome/9586-genome-2020-1.html
 
9) Guidelines on COVID-19 in vitro diagnostic tests and their performance, EUROPEAN COMMISSION, Brussels, 15.4.2020 C (2020) 2391 final.
 
10) Diao B, Wen K, CHEN J, et al : Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein : medRxiv, 2020. https://dx.doi.org/10.1101/2020.03.07.20032524
 
P.951 掲載の参考文献
1) 田村研治 : 第1回国立がん研究センター中央病院における外来化学療法. 外来癌化学療法 1 (1) : 58-61, 2010.
 
2) 医療イノベーション推進センター : NCCN Clinical Guidelines in Oncology 膵癌 (腺癌) 2019年 第3版, PANC-5, 2019.
 
3) 日本膵臓学会 : 膵癌診療ガイドライン 2016年版 RS10, 122-124, 2016.
 
4) 濱田晋, 正宗淳, 下瀬川徹 : CA19-9-検査編. 臨床検査 59 : 632-637, 2015.
 
5) Mattiucci GC, Morganti AG, Cellini F, et al : Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma : A Pooled Analysis. Transl Oncol 12 (1) : 1-7, 2019.
PubMed
6) 花田浩之, 竹岡啓子, 野村朋子, 他 : 電気化学発光免疫測定法を用いた「エクルーシス試薬CA19-9 II」の評価. 医学と薬学 52 (6) : 1007-1014, 2004.
Medical*Online
7) 三橋知明 編 : 臨床検査ガイド 2015年改訂版, 文光堂, 東京, 2015.
 

【Cosmetic】

P.956 掲載の参考文献
1) 今原広次, 伊藤泰美 : メラニン形成におよぼすプラセンタエキストラクトの影響. 粧技誌 16 (1) : 10-14, 1982.
 
2) 坪井誠 : 天然成分を利用した機能性活性成分の開発. オレオサイエンス 11 (155) : 13, 2011.
 
3) 藤田晴久, 櫻井敏晴, 吉田正也, 富島滋 : Glycyrrhitinic acidの一般抗炎症効果. 応用薬理 19 (3) : 481-484, 1980.
 
4) 長濱通子, 船坂陽子, 市橋正光 : 日本人に適すると考えられたグリコール酸を用いたケミカルピーリング. 皮膚 42 : 503-508, 2000.
 
5) イプロス医薬食品技術 (最終閲覧日 : 2020/4/24) https://ls.ipros.jp/popup/download/catalog/?objectExpression=2-1595733&sourceObjectId=2495645&sourceObjectType=1&hub=45+google
 

書評

最近チェックした商品履歴

Loading...